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MaBACKGROUND Recent guidelines recommend assessment of systolic function and ﬁlling pressures to augment
angiographic grading of cardiac allograft vasculopathy (CAV); however, no data exist on the utility of these guidelines.
OBJECTIVES The aims of this study were to evaluate whether the assessment of systolic and diastolic graft function, in
addition to angiography, improves recognition of patients at high risk of graft loss and to assess the ability of adult
ﬁlling-pressure thresholds to discriminate graft dysfunction in pediatric patients.
METHODS This study reviewed Pediatric Heart Transplant Study data from 1993 to 2009. Graft dysfunction was deﬁned
as signiﬁcant systolic dysfunction (ejection fraction [EF] <45%) or the presence of restrictive hemodynamic features.
Additional pediatric hemodynamic cutpoints of right atrial pressure (RAP) >12 mm Hg or pulmonary capillary wedge
pressure (PCWP) >15 mm Hg were analyzed.
RESULTS In the study, 8,122 angiograms were performed in 3,120 patients, and 70% of patients had at least 1
angiogram. Angiographic incidence of CAV was 5%, 15%, and 28% at 2, 5, and 10 years, respectively, and most disease
was mild. The presence of graft dysfunction identiﬁed patients at greater risk for graft loss even in children with mild
angiographic vasculopathy (p < 0.0001). An RAP >12 mm Hg or a PCWP >15 mm Hg was sufﬁcient to detect patients at
high risk of graft loss even with mild angiographic disease.
CONCLUSIONS Patients with only mild angiographic CAV have signiﬁcantly better outcomes than do patients with
moderate or severe disease. The presence of an EF <45%, an RAP >12 mm Hg, or a PCWP >15 mm Hg identiﬁes children
at increased risk of graft loss even in the presence of only mild angiographic vasculopathy. (J Am Coll Cardiol
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ABBR EV I A T I ON S
AND ACRONYMS
CAV = cardiac allograft
vasculopathy
EF = ejection fraction
ISHLT = International Society
for Heart and Lung
Transplantation
PCWP = pulmonary capillary
wedge pressure
RAP = right atrial pressure
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548conditional to 1-year survival, there is little
difference in outcomes among eras. Midterm
and late graft loss primarily occurs as the
result of 1 of 3 etiologic factors: primary graft
dysfunction, infection, and cardiac allograft
vasculopathy (CAV). CAV is the second lead-
ing identiﬁable cause of graft loss beyond
3 years post-transplant in children, and it
accounts for approximately 25% of late
deaths (1).
CAV is a chronic graft complication caused
by immune and nonimmune processes (2–4). Earlier
studies showed that factors such as donor age, recip-
ient age, human leukocyte antigen (HLA) mismatch,
allosensitization, frequent cellular rejection, and
rejection with hemodynamic compromise are associ-
ated with increased risk of CAV in children (1,5–8).
Single-center studies and a large collaborative retro-
spective analysis of the PHTS (Pediatric Heart Trans-
plant Study) demonstrate that CAV is an important
complicationwith a steady increase in prevalence over
time. Rates of angiographically identiﬁed disease in-
crease from 5% at 1 year to 15% by 5 years and to as
much as 30% by 10 years post-transplant (6). Analysis
of outcomes after initial diagnosis of disease have been
limited, with registry data demonstrating a 20% to
40% graft loss by 6 to 10 years after discovery (1,6) and
very little data reﬂecting the rate of graft loss stratiﬁed
by disease severity.SEE PAGE 558In an attempt to deﬁne CAV for clinicians more
clearly, the International Society for Heart and Lung
Transplantation (ISHLT) released an updated set of
nomenclature guidelines in 2010 (9). Important
changes in this update included the addition of
measures of systolic and diastolic graft function to
the angiographic assessment of CAV. These addi-
tional metrics are designed to increase sensitivity to
microvascular disease and consequent myocardial
ﬁbrosis, which cannot be well described by angiog-
raphy. Although these recommendations were built
around adult experience and data (10), the guidelines
suggest application to pediatric patients, even though
similar data and analyses in children are limited to
small, single-center experiences (11,12).
This study sought to evaluate the validity of the
ISHLT nomenclature guidelines in a large pediatric
patient cohort and to examine the impact of func-
tional assessment added to angiographic grading on
the identiﬁcation of patients at risk for death or
retransplantation. We hypothesized that: 1) the
addition of assessments of systolic performance by
ejection fraction (EF) and diastolic ﬁlling byhemodynamic measurement would identify patients
with less severe angiographic disease at increased
risk for graft loss; and 2) the hemodynamic cutpoints
proposed in the guidelines may not be sufﬁciently
sensitive to discriminate graft dysfunction in younger
patients. To test these hypotheses, we retrospectively
graded the degree of vasculopathy in the patients
followed through the PHTS dataset by using a
combination of angiographic data, markers of sys-
tolic dysfunction, and restrictive ﬁlling and compared
rates of graft loss with those found using an
angiography-alone grading system.
METHODS
DATA COLLECTION. The multicenter PHTS collabo-
rative collects data on heart transplantation from its
member sites throughout the United States, Canada,
and the United Kingdom. At the time of this analysis,
data were contributed by 35 North American trans-
plant centers and 1 U.K. center. Institutional review
board approval is required from all member sites
before submission of data to the PHTS, and certiﬁca-
tion of institutional review board approval is kept
onsite at the PTHS data collection center. The PHTS
collects data on all included patients from the time of
their listing through the most recent annual follow-
up, including information on patients’ status, trans-
plant, rejection, infection, coronary artery evaluation
and revascularization, malignant disease, and death.
Data on patients listed for heart transplantation who
are <18 years of age are collected by the PHTS, with
patients censored when they are removed from listing
or on transition to another hospital. For this analysis,
all patients who were followed in this pediatric
registry and who underwent heart transplantation
between January 1993 and December 2009 with at
least 1 coronary angiogram reported to the PHTS were
included with follow-up through December 31, 2010.
Patient-related variables included initial listing
demographic factors, cardiac disease, listing status,
and complications, as well as donor characteristics
including sex, age, weight, cause of death, and
medical history. Data on management, outcomes,
and annual follow-up were further examined,
including angiographic grading, echocardiographic
measures of systolic function through reported EF,
invasive hemodynamic measurements, death, and
retransplantation.
ANGIOGRAPHIC ANALYSIS. Angiographic data are
reported to the PHTS for any patient who has had
angiographic examination in the prior year during
annual data submission. Information about coronary
angiography has been a core data element collected
TABLE 1 Angiographic and Functional Nomenclature of CAV*
Grade Description
CAV-0 (not signiﬁcant) No detectable angiographic lesion
CAV-1 (mild) LM <50%, any primary vessel <70%, or any branch <70%
CAV-2 (moderate) LM 50%–70%, a primary vessel $70%, or branch $70% in
branches of 2 systems
CAV-3 (severe) LM $70%, 2 or more primary vessels $70%, or branch stenoses
$70% in all 3 systems
Functional Parameters
Functional
upgrading
Evidence of signiﬁcant systolic dysfunction (EF <45%)
Evidence of restrictive hemodynamics or CI <2.1 l/min/m2
*Tabular representation of the angiographic descriptions of various degrees of CAV by angiography (upper part of
table) and functional criteria for upgrading mild or moderate angiographic disease to severe (CAV-3) grading
(lower part of table). Primary vessels: proximal and middle one-third of left anterior descending, left circumﬂex,
ramus, and dominant or codominant right coronary artery with posterior descending and posterolateral branches.
Branch vessels: distal one-third of any primary vessels or any segment within a large septal perforator, diagonal,
and obtuse marginal branches or any portion of a nondominant right coronary artery. If any functional abnor-
mality is present in combination with CAV-1 or CAV-2 angiographic changes, the patient is “upgraded” to CAV-3.
CAV¼ cardiac allograft vasculopathy; CI¼ cardiac index; EF¼ ejection fraction; LM¼ left main coronary artery.
J A C C V O L . 6 6 , N O . 5 , 2 0 1 5 Kindel et al.
A U G U S T 4 , 2 0 1 5 : 5 4 7 – 5 7 Functional Assessment and Graft Loss in Allograft Vasculopathy
549since the inception of the PHTS. Although the data
forms have evolved over time, they provide speciﬁc
information about the presence and degree of
stenosis in major and minor coronary vessels, the
pattern of coronary artery dominance, and whether
the lesion appears in the proximal, middle, or distal
third of the artery. To determine the grade of CAV in
each patient, all submitted angiogram forms were
analyzed, and the angiographic criteria were applied
according to the most recent ISHLT guidelines (9). In
this manner, an angiographic score of CAV-1, CAV-2,
or CAV-3 was created for each patient (Table 1).
SYSTOLIC FUNCTION AND HEMODYNAMIC ASSESSMENT.
In addition to angiographic data, these forms also
include the indication for the study, the EF and
method obtained, the presence or absence of seg-
mental wall motion abnormalities, and the type of
angiographic injections performed. Although the EF
may appear in other areas in the data submission,
only those values reported on the angiography form
were used in the analysis. Hemodynamic data are
reported on the annual status follow-up form for any
patient who had a cardiac catheterization procedure
in the 12 months before each data submission period,
along with an indication of the timing of collection.
These data were reviewed and collated along with the
angiographic data. All hemodynamic values available
and collected within 3 months of the discovery of
angiographic disease were included in the analysis,
and those values reported more remotely were
audited. Echocardiographic measures of diastolic
function have not been collected by the PHTS data-
base and therefore were not included in the current
analysis.
Any abnormality in systolic function, as assessed
by EF, or in diastolic performance, as assessed by
right atrial pressure (RAP) or pulmonary capillary
wedge pressure (PCWP), was considered a “functional
abnormality” for the purpose of analyzing the impact
of graft performance on graft survival after a diag-
nosis of vasculopathy. In accordance with the ISHLT
guidelines, any EF <45% was considered a sign of
signiﬁcant systolic dysfunction, an EF of 44% to 35%
was considered to represent moderate systolic
dysfunction, and an EF <35% indicated severe
dysfunction. Hemodynamic cutpoints of RAP >20
mm Hg or PCWP >25 mm Hg were initially assessed as
adult markers of restrictive graft hemodynamics.
These guidelines were selected on the basis of adult
data and therefore may not provide ideal threshold
derangements for pediatric patients. To examine this
hypothesis, we deﬁned an RAP #12 mm Hg and a
PCWP #15 mm Hg as normal, an RAP of 13 to 20 mm Hg
and a PCWP of 16 to 25 mm Hg as moderately elevated,and an RAP >20 mm Hg or a PCWP >25 mm Hg as
severely restrictive, on the basis of the ﬁndings of 2
single-center pediatric analyses (11,13).
STATISTICAL ANALYSES. Descriptive statistics for
continuous variables are presented as mean and range;
categorical variables are presented as frequency
and percent. The criterion for statistical signiﬁcance
was set at the traditional a¼0.05 level. Various Kaplan-
Meier nonparametric curves demonstrating graft sur-
vival for patients with each classiﬁcation of CAV were
generated with respect to time to graft loss (death or
retransplant) after the ﬁrst discovery of CAV. Data on
freedom from disease represent descriptive analysis
over the pool of all follow-up observations with a
varying number of time points per patient. Patients are
censored from repeat tabulation once discovered with
disease of any single grade, but they remain at risk for
development of amore severe grade of CAV. Therefore,
patients may appear on multiple curves over time.
When EF values or hemodynamic values were not
available, these patients were audited from those as-
pects of this study involving functional analysis.
RESULTS
PATIENT POPULATION. Our analysis included 3,120
pediatric heart transplant recipients from 1993 to 2009.
Angiography was commonly performed; 2,078 (67%)
patients had at least 1 angiogram, and a total of 8,122
angiograms were performed in the study cohort. For
patients surviving 2, 5, and 10 years post-transplant,
the rate of coronary angiography rose from 61% to
83% to 98%, respectively, with most programs
reporting routine assessments annually or every other
year. Most of these studies (96%) were done with a
reported indication of “routine per protocol,” with
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550another 3% done for “symptoms or graft dysfunction.”
The remaining 1% of angiograms was performed for
reasons including: “noninvasive testing positive for
[CAV],” “other concern for [CAV],” “follow-up to prior
intervention,” or “as part of a research protocol.”
ANGIOGRAPHIC DISEASE. Report of angiographic
disease was relatively rare, and most disease was
mild. Overall, 7,273 (89.6%) of angiograms showed no
signiﬁcant coronary disease (CAV-0). Angiographic
disease was primarily mild (CAV-1; 7.8%) with a very
small proportion of moderate (CAV-2; 1.4%) or severe
(CAV-3; 1.2%) disease reported. The incidence of any
angiographic disease was 2.3%, 13.9%, and 27.5% at
1, 5, and 10 years post-transplant, respectively. The
incidence of moderate disease was 0.2%, 2.0%, and
5.4% at 1, 5, and 10 years, respectively, and it wasFrom CAV by Disease Severity and Age at Transplant
Years After Transplant
Any CAV disease (n = 403)
ess than 1 year (n = 678, events = 113)
1 to 21 years (n = 695, events = 162)
1 to 10 years (n = 699, events = 128)
CAV-3 (n = 67)
CAV-1 (n = 337) CAV-2 (n = 80)
5 10 15
p (overall) < 0.0001
Years After Transplant
5 10 15
p (overall) < 0.0001
rdiac allograft vasculopathy (CAV) by disease severity in patients who
t from 1993 to 2009 (n ¼ 2,078). (B) Freedom from CAV by age at
s who received a transplant from 1993 to 2009 (n ¼ 2,078). Actuarial
e over time is stratiﬁed by age at time of transplantation. Time 0 is
ed areas indicate 70% conﬁdence limits. Event: CAV after transplant.0.2%, 2.2%, 4.4% for severe disease at 1, 5, and 10
years, respectively (Figure 1A). Angiographic disease
was seen signiﬁcantly more frequently in older chil-
dren (p < 0.0001), as shown in Figure 1B, in which the
groups are stratiﬁed by age at time of transplant.
SYSTOLIC FUNCTION ASSESSMENT. Left ventricular
EF was reported in conjunction with the angiographic
data in 56.2% of the 8,122 angiograms performed.
Analysis of these follow-up events in which both
angiographic data and EF were reported revealed an
EF >45% in 96.5% of cases, whereas an EF between
30% and 45% was reported in 3.2%, and only 0.4%
showed severe systolic dysfunction with EF <30%
(Table 2). A lower EF correlated with more severe
angiographic disease (p < 0.0001), in which no
adjustment was made for multiple observations.
Patients with a normal coronary angiogram (CAV-0)
rarely had an EF of <45% (2.8%), whereas patients
with severe angiographic disease (CAV-3) had an
EF <45% in 16.1% of angiograms (Table 2).
HEMODYNAMIC ASSESSMENT. Hemodynamic data
were reported for 7,787 of 8,122 (95.9%) angiograms.
For 58.0% of angiograms, hemodynamic variables
were collected within 3 months of angiography and
were therefore included in the following analyses.
Using the previously described cutpoints for restric-
tive physiology, 1.2% of angiograms were associated
with abnormal hemodynamic measurements. Of
those, 0.7% had severely elevated RAP (>20 mm Hg),
and 0.6% hadmarked elevation of PCWP (>25 mmHg).
Table 3demonstrates the hemodynamic derangements
found in patients in relation to the degree of angio-
graphic disease at ﬁrst discovery. Using the extended
cutpoints of an RAP>12 and PCWP>15, another 3.7% of
angiograms coincided with an RAP between 13 and
20 mm Hg, and 5.8% coincided with a PCWP between
16 and 25 mm Hg.
ASSOCIATION OF DEGREE OF GRAFT DYSFUNCTION
WITH RATES OF GRAFT LOSS. Left ventricular
EF showed a signiﬁcant correlation with graft loss
(death or retransplant). Patients with any degree ofTABLE 2 Association Between Angiographic Vasculopathy Grade
and Ejection Fraction*
EF >45% EF 30%–45% EF <30%
CAV-0 (n ¼ 4,068) 3,957 (97.2) 104 (2.6) 7 (0.2)
CAV-1 (n ¼ 383) 347 (90.6) 31 (8.1) 5 (1.3)
CAV-2 (n ¼ 83) 73 (88.0) 7 (8.4) 3 (3.6)
CAV-3 (n ¼ 31) 26 (83.9) 4 (12.9) 1 (3.2)
Total (n ¼ 4,565) 4,403 (96.5) 146 (3.2) 16 (0.3)
Values are n (%). *N ¼ 4,565 angiograms with ejection fractions reported,
p < 0.0001.
Abbreviations as in Table 1.
TABLE 3 Association of Hemodynamic Abnormalities With Angiographic Vasculopathy Grade*
RAP #12 mm Hg RAP 13–20 mm Hg RAP >20 mm Hg PCWP #15 mm Hg PCWP 16–25 mm Hg PCWP >25 mm Hg
CAV-0 (n ¼ 4,306) 4,160 (96.61) 125 (2.90) 21 (0.49) 4,073 (94.59) 220 (5.11) 13 (0.30)
CAV-1 (n ¼ 335) 294 (87.76) 36 (10.75) 5 (1.49) 283 (84.48) 42 (12.54) 10 (2.99)
CAV-2 (n ¼ 58) 43 (74.14) 10 (17.24) 5 (8.62) 51 (87.93) 5 (8.62) 2 (3.45)
CAV-3 (n ¼ 15) 10 (66.67) 3 (20.00) 2 (13.33) 8 (53.33) 7 (40.67) 0 (0.00)
Total (n ¼ 4,714) 4,507 (95.6) 174 (3.7) 33 (0.7) 4,415 (93.6) 274 (5.8) 25 (0.6)
Values are n (%). *N ¼ 4,714 angiograms with hemodynamics reported with 3 months of angiogram (RAP p < 0.0001; PCWP p < 0.0001).
RAP ¼ right atrial pressure; PCWP ¼ pulmonary capillary wedge pressure; other abbreviations as in Table 1.
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551angiographic vasculopathy and an EF <45% had
signiﬁcantly worse graft survival than did patients
with an EF >45% (p ¼ 0.0009) (Figure 2A). There was
no difference, however, between patients withFIGURE 2 Graft Survival After Diagnosis of Any CAV by EF, RAP, or
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552vasculopathy showed that an RAP >12 mm Hg was
associated with higher rates of graft loss compared
with patients with any degree of angiographic CAV
and an RAP #12 mm Hg (Figure 2B). Severe RAP
elevation (>20 mm Hg) was associated with a further
increase in risk of graft loss, especially after year 2
after the ﬁrst discovery of any CAV. Patients with a
PCWP #15 mm Hg had signiﬁcantly better graft sur-
vival over time than did patients with a PCWP of 16 to
25 mm Hg or >25 mm Hg (Figure 2C). Furthermore,rvival After Diagnosis of Any CAV by Angiography Only and
2 3 4 5 6 7 8 9 10 11 12 13 14 15
p (overall) < 0.0001
Years After Diagnosis of any CAV
2 3 4 5 6 7 8 9 10 11 12 13 14 15
p (overall) < 0.0001
Years After Diagnosis of any CAV
CAV-1 (n = 333, graft loss = 107)
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CAV-2 (n = 48, graft loss = 26)
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AV-3 with upgrading (n = 45, graft loss = 24)
CAV-2 (n = 44, graft loss = 24)
er diagnosis of any CAV by angiography only in patients who received
93 to 2009 (n ¼ 405). Graft survival after the discovery of angio-
ﬁed by angiographic grading without consideration of functional
rvival after diagnosis of any CAV with upgrading in patients who
t from 1993 to 2009 (n ¼ 405). Graft survival after the discovery of
stratiﬁed by angiographic grading and functional analysis using high
, RAP $20, PCWP $25). Time 0 is discovery of disease, and shaded
ence intervals. Shaded areas represent 70% conﬁdence limits. Event:
osis. CAV-1 ¼ mild angiographic disease; CAV-2 ¼ moderate angio-
-3 ¼ severe angiographic disease or CAV-1 or CAV-2 plus any func-
ther abbreviations as in Figure 2.those patients with the most severe PCWP elevations
had very high early rates of graft loss and signiﬁcantly
worse graft survival compared with the other 2
groups.
COMPARISON OF ANGIOGRAPHY ALONE WITH ANGIO-
GRAPHIC AND FUNCTIONAL ASSESSMENT. Figure 3A is a
Kaplan-Meier curve examining rates of graft loss over
time after the ﬁrst discovery of CAV for patients
stratiﬁed by angiographic ﬁndings without consid-
ering EF or ﬁlling pressures. Patients with mild
angiographic changes had the best graft survival,
whereas those with moderate or severe angiographic
disease had signiﬁcantly increased graft loss, espe-
cially in the ﬁrst year after discovery (p < 0.0001).
One and 5-year graft survival rates, on the basis of
degree of angiographic vasculopathy, were approxi-
mately 82% and 67% for mild (CAV-1), 65% and 45%
for moderate (CAV-2), and 35% and 25% for severe
(CAV-3) disease, respectively.
Figure 3B shows graft loss over time from ﬁrst
angiographic discovery of disease with measures of
systolic and diastolic function now included in
grading. Speciﬁcally, those patients with mild (CAV-1)
or moderate (CAV-2) angiographic changes and a
single functional abnormality are “upgraded” to
CAV-3. The patients with an EF >45%, an RAP
#20 mm Hg, a PCWP #25 mm Hg, and only mild
angiographic disease had signiﬁcantly lower rates of
graft loss (p < 0.001) than did patients with moderate
angiographic disease or severe angiographic disease
or those with any degree of angiographic CAV and a
single functional abnormality. Additionally, this
curve demonstrated that patients with moderate
angiographic disease combined with normal systolic
function and hemodynamic values have rates of graft
loss similar to patients with severe angiographic dis-
ease or those with mild or moderate angiographic
disease coupled with functional abnormalities.
The Central Illustration shows a Kaplan-Meier curve
with the less severe deﬁnition of restrictive ﬁlling as
an RAP >12 mm Hg or a PCWP >15 mm Hg. A similar
pattern is shown in which patients with mild angio-
graphic changes, an EF >45%, and normal ﬁlling
pressures have signiﬁcantly better graft survival than
do patients with more severe angiographic disease or
those with mild or moderate coronary changes and a
single functional derangement (p < 0.0001). By using
these more inclusive hemodynamic cutpoints, graft
survival after the ﬁrst discovery of moderate angio-
graphic disease and an EF >45%, an RAP #12 mm Hg,
and a PCWP #15 mm Hg (CAV-2) again was not
signiﬁcantly different from graft survival in patients
with either severe angiographic disease or mild or
CENTRAL ILLUSTRATION Graft Survival After Diagnosis of CAV
Kindel, S.J. et al. J Am Coll Cardiol. 2015; 66(5):547–57.
Graft survival after discovery of angiographic cardiac allograft vasculopathy (CAV) stratiﬁed by angiographic grading and functional analysis using lower cut points
(ejection fraction [EF] <45%, right atrial pressure [RAP] >12, pulmonary capillary wedge pressure [PCWP] >15). Time 0 is discovery of disease, and shaded areas
are 70% conﬁdence intervals. CAV-1 ¼ mild angiographic disease; CAV-2 ¼ moderate angiographic disease; CAV-3 ¼ severe angiographic disease or CAV-1 or CAV-2
plus any functional abnormality.
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553moderate angiographic disease and a single func-
tional abnormality (Central Illustration).
ANALYSIS OF PATIENTS WITH MILD ANGIOGRAPHIC
DISEASE. As noted earlier, most cases of CAV in
children are mild, and as shown in Figures 3A to 3C,
patients with mild angiographic disease have lower
rates of graft loss than do patients with CAV-2 or
CAV-3. To clarify the effects of hemodynamic changes
in patients with mild angiographic disease, we per-
formed an additional analysis including only patients
with mild coronary changes. In Figure 4, Kaplan-
Meier survival curves demonstrate the effect of any
abnormal functional parameter on patients with mild
angiographic disease. In Figure 4A, the more severe
cutpoints of an EF <45%, an RAP >20 mm Hg, or
a PCWP >25 mm Hg are used and demonstrate a
signiﬁcant difference in graft survival (p <0.001)highlighted by very early attrition for those patients
with any abnormal functional parameter. Figure 4B
uses the lower pressure cutpoints of an RAP >12
mm Hg or a PCWP >15 mm Hg or an EF <45%
and continues to show a statistically signiﬁcant
(p <0.002) but less dramatic rate of graft loss for
patients with CAV-1.
DISCUSSION
This large study examined the diagnosis and out-
comes in CAV in children, including 3,120 pediatric
patients from 36 centers and >8,000 angiographic
events. Further, this analysis examined functional
and hemodynamic derangements associated with
CAV as a risk factor for graft loss in a multicenter
cohort and assessed the current ISHLT CAV nomen-
clature guidelines in a pediatric cohort. The ﬁndings
FIGURE 4 Graft Survival After Diagnosis of CAV-1 and After Diagnosis of
CAV-1 Versus CAV-3 Redeﬁned Upgrades
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(A) Graft survival after diagnosis of mild angiographic coronary allograft vasculopathy
(CAV-1) in patients who received a transplant from 1993 to 2009 (n ¼ 315). Effect of
abnormal graft function (EF <45%, RAP $20, PCWP $25) on graft survival after ﬁrst
discovery of CAV-1. (B) Graft survival after diagnosis of CAV-1 versus CAV-3 redeﬁned
upgrades in patients who received a transplant from 1993 to 2009 (n ¼ 346). Effect of
abnormal graft function (EF <45%, RAP >12, PCWP >15) on graft survival after ﬁrst
discovery of CAV-1. Time 0 is ﬁrst discovery of mild angiographic disease. Shaded areas
represent 70% conﬁdence limits. Event: graft loss after diagnosis. Abbreviations as in
Figure 2.
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554of this study validate the inclusion of measures of
systolic function and ﬁlling pressures into the grading
of CAV in children after heart transplant, and they
indicate that an EF <45%, an RAP >12 mm Hg, or a
PCWP >15 mm Hg in the setting of even mild angio-
graphic vasculopathy is associated with an increased
risk for graft loss.
CAV in children is less common than was demon-
strated in earlier studies of adult heart transplant
recipients (2,14), with overall rates of angiographicdisease rising from 2% to nearly 30% over 10 years of
graft life. The current data are similar to the rates
seen in the PHTS analysis by Pahl et al. (6) from a
decade earlier; however, with a greater length of data
collection, the current report is able to show a con-
stant hazard ratio out to 15 years of patient follow-up.
Although the study is limited to the detection of
angiographic disease and cannot fully account for
patients with microvascular disease or those with
sudden death resulting from coronary lesions, the
earlier work by Pahl et al. (6) showed a similar
reduced incidence of CAV in children versus adults by
comparison with data from the Cardiac Transplant
Research Database. As shown in this study and others
(1,6,8), an age gradient exists, with the youngest pa-
tients having the lowest rate of coronary disease
development over time (Figure 1B). This ﬁnding is
likely related to several issues, including the relative
naiveté of the infantile immune system leading to
increased graft accommodation, younger age of do-
nors, and less frequent rejection (and speciﬁcally,
rejection with hemodynamic compromise) in these
patients (7,8). Furthermore, children undergoing
heart transplant tend to have less obesity, diabetes,
hyperlipidemia, and hypertension than do typical
adult transplant recipients, thus creating a healthier
host environment for graft longevity (2,3).
In addition to seeing disease less frequently, most
disease that was discovered was mild, as reported
previously (6). The current data, however, now
include 3 times as many patients with at least 1
angiogram and signiﬁcantly more patients with out-
comes of death or retransplantation, thus allowing for
a more robust analysis of these events. The lack of
severe disease is again likely multifactorial, repre-
senting the quality of donors (younger age, lack of
donor hypertension, diabetes, hyperlipidemia, or
coronary disease), the low rates of signiﬁcant rejection
in children after heart transplant, and the otherwise
healthy milieu of the pediatric transplant recipient. In
addition, the coronary artery changes in these chil-
dren may be more subtle than in adults, and detection
may be challenged by practitioners’ experience,
vessel size, and other unknown factors (15–17). The
PHTS only recently began collecting graded data for
intravascular ultrasound, and the study does not
contain data on cardiac computed tomography or
cardiac magnetic resonance, which could have offered
additional views into the degree of disease. However,
these modalities are not routinely used in most pedi-
atric centers at this time and are currently undergoing
study as potential adjunctive means to identify CAV.
Therefore, the analysis of angiographic ﬁndings is
quite applicable to current pediatric practice.
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555Although moderate or severe vasculopathy is un-
common, when it is discovered the outcomes are
quite severe. With greater patient numbers than in
earlier series, we were able to examine moderate and
severe angiographic disease separately, and a striking
gradient effect was demonstrated (Figures 3 and 4).
Mild CAV suggests a rather benign outcome with
survival rates comparable to general outcomes for
children after heart transplant. In contrast, moderate
angiographic disease alone (without hemodynamic
assessment) correlates with a higher rate of graft loss,
with 50% of patients dead or undergoing repeat heart
transplantation by 2 years and 67% by 5 years after
discovery. Severe angiographic disease portends a
very poor prognosis; 75% of children experience graft
loss within 3 years of the initial diagnosis.
The available data from earlier registry reviews
reported graft loss without delineation of disease
severity (1) or stratiﬁed by angiographic grading (6).
The current study aimed to go further and includes
functional changes as recommended by the most
recent ISHLT guidelines (9). When considering the
low rate of moderate or severe angiographic disease
seen in children, speciﬁcally the lack of high-grade
proximal stenosis, investigators have questioned the
value of angiographic studies for the assessment of
CAV in children (15,18). Hemodynamic and functional
changes are relatively easily obtained markers for
small vessel and microvascular vasculopathy that can
lead to ﬁbrosis and graft dysfunction before graft loss
(19). The revised nomenclature suggested by the
ISHLT attempts to capture these interactions and help
clinicians to deﬁne more clearly the severity of vas-
culopathy that may not be easily detected by angi-
ography alone.
Although the EF has not been studied directly as a
marker of more severe CAV in children, the presence
of elevated ﬁlling pressures in pediatric heart trans-
plant recipients has been reported before in a few
small, single-center studies. More than 2 decades
ago, it was demonstrated that in children after heart
transplant, a larger rise in ﬁlling pressures after a
saline bolus was associated with graft dysfunction
(20). Law et al. (11) demonstrated an association be-
tween elevated ﬁlling pressures and the development
of CAV. Neither study, however, was formulated to
evaluate the effect of hemodynamic changes in pa-
tients with angiographic CAV on outcome. In an
analysis by Aiygari et al. (12), looking at single-center
data over a 20-year period, the investigators found
that elevation of ﬁlling pressures with an RAP >10.4
mm Hg or a PCWP >13.7 mm Hg were associated with
a higher risk of retransplant or death. Due to the
small sample size in their analysis, the investigatorsreviewed hemodynamic changes in all patients who
had at least 1 angiogram (including those with no
angiographic CAV), thereby demonstrating that
elevation of ﬁlling pressures alone is a risk factor for
graft loss. By including those without angiographic
disease, however, the study was limited in its ability
to determine any interaction between the presence
and severity of angiographic changes and ﬁlling
pressures as a marker of more severe vasculopathy.
In the current study, we are able to associate func-
tional derangements with high rates of graft loss and
demonstrate that the ISHLT nomenclature guidelines
are relevant in children. Figure 4 demonstrates that
reclassifying any patient with at least 1 signiﬁcant
functional abnormality to the “severe” or CAV-3
classiﬁcation does identify an at-risk population.
Notably, another effect of this change is to dampen the
effect of a diagnosis of “severe” CAV inasmuch as the
CAV-3 group outcomes, including patients with func-
tional abnormalities, appear more similar to those
observed in angiographic CAV-2. This ﬁnding is
noteworthy because it may indicate that patients with
severe proximal coronary disease (although quite rare
in pediatric cohorts) are at particularly high risk of
graft loss, whereas those with functional abnormal-
ities and less severe angiographic disease have a
slightly more benign outlook. However, these patients
remain clearly differentiated from the patients with
only mild angiographic changes and continue to have
a very high rate of graft loss (nearly 50% by 2 years and
70% by 5 years after disease discovery).
Recognizing that the patients with only mild vas-
culopathy are by far the most prevalent and have
signiﬁcantly better outcomes, we repeated the anal-
ysis and focused on the group with mild angiographic
disease, to remove the effects of patients with mod-
erate or severe coronary artery changes. In these pa-
tients, the presence of any functional derangement is
associated with a greater risk of graft loss. Using the
high ﬁlling pressure deﬁnition of restrictive hemo-
dynamics, the small group of patients with mild
angiographic changes and severe ﬁlling pressure el-
evations had very poor outcomes. Nearly 80% of
these patients either died or underwent retransplant
procedures within 2 years of disease discovery.
When considering the current guidelines in a pe-
diatric patient group, we were concerned that an
overly severe deﬁnition of restrictive physiology
would fail to identify some pediatric patients at risk
for early graft loss. In the work by Law et al. (11), the
mean RAP and PCWP in children with CAV were 11
mm Hg and 14 mm Hg, respectively, both signiﬁcantly
higher than in matched controls (RAP, 6 mm Hg;
PCWP, 8 mm Hg). In the analysis by Aiyagari et al.
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suggested that an RAP of 10 mm Hg and a PCWP of
12 mm Hg was indicative of CAV and that an RAP
>10.4 mm Hg or a PCWP >13.7 mm Hg was associated
with a higher rate of graft loss.
To examine pediatric thresholds of restrictive
ﬁlling, we chose cutpoints in line with those earlier
analyses. On the basis of the combined clinical expe-
rience of the writing group, we evaluated those pa-
tients with an RAP >12 mm Hg or a PCWP >15 mm Hg
for increased risk of graft loss. When applying these
“pediatric” standards to patients with less severe
angiographic disease, a signiﬁcant difference in out-
comes was found compared with patients with mild
CAV and normal functional studies. Speciﬁcally, sub-
jects with CAV-1 and normal EF, RAP, and PCWP had a
graft survival rate of 50% at 10 years after the diag-
nosis of CAV; the presence of just 1 functional abnor-
mality indicated a 50% risk of graft loss by 3 years. In
this manner, the presence of even a single functional
change helps identify patients who could be offered
more frequent follow-up and potentially changes in
therapy to attempt to extend graft survival.
STUDY LIMITATIONS. This study is limited by several
factors, as expected in a retrospective analysis of a
large database subject to the selection and data
collection biases typical of such analyses. There is
potential for misreporting of data and mistiming of
data entry. In particular, nearly 42% of the patients
with angiograms had neither hemodynamic values
nor an EF reported within 3 months of angiography,
and these missing data are potential confounders
of our analysis. Adjudication and blinded review of
echocardiograms and angiograms was not possible
given the large scope and breadth of patients
reviewed. Although echocardiographic parameters
are included in the ISHLT deﬁnition of restrictive
physiology, they are not available through PHTS data
collection and therefore could not be assessed in the
current review. Additionally, screening protocols are
not standardized among centers. This limitation led
to some of the missing functional data and potential
for bias because small numbers of patients were
referred for angiography in response to symptoms or
dysfunction. Because of the structure of the PHTS,
patients are removed from analysis if they transition
to a non-PHTS facility, and this protocol removed
some outcomes from the analysis. Finally, the pres-
ence of other graft disease such as rejection,
nonspeciﬁc graft dysfunction, effusion, or valve
regurgitation—all of which could skew timing of dis-
ease discovery or functional measures—cannot be
accounted for in this analysis. However, review ofdonor characteristics did not reveal an association
between a donor death resulting from head trauma
and later elevation of ﬁlling pressures.
Another key issue in the interpretation of these data
is that the management decisions, including immu-
nosuppression, treatments for CAV, and the perfor-
mance of a repeat transplant procedure, were made
solely on the basis of clinical decision making at the
various institutions. The decision to offer retrans-
plantation would be expected to be inﬂuenced by the
severity of angiographic changes, as well as by prac-
titioners’ concerns about hemodynamics. Finally, this
study does not indicate that normal hemodynamics
should be considered overly reassuring. In patients
with moderate or severe angiographic changes even
before application of functional assessments, there
remains a high rate of graft loss, as recently described
in a single-center experience by Hong et al. (21).
CONCLUSIONS
Despite the expected limitations, the current work
represents a large analysis of CAV in children after
heart transplantation and presents a multicenter
assessment of the effect of functional changes in
children with CAV on graft survival. CAV is a common
long-term complication of heart transplant in children
that is detected by angiography in nearly 30% of pa-
tients within 10 years of transplant. Most cases of this
disease are mild by angiographic standards and, when
coupled with normal hemodynamics and normal sys-
tolic function by echocardiogram, portend reasonable
graft survival. Because of the detailed data collection
at the PHTS, we are able to analyze a high level of
complexity in the interactions between angiographic
and functional disease. Furthermore, the large num-
ber of patients, angiograms, and functional assess-
ments allowed for analysis of the cutpoints offered by
the ISHLT guidelines. The current study would sug-
gest that pediatric practitioners should consider an
RAP >12 mm Hg or a PCWP >15 mm Hg to be a con-
cerning ﬁnding in a child after heart transplant.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
Systolic ventricular dysfunction and diastolic ventricular
dysfunction, as measured by reduced EF or elevated
ﬁlling pressures, are important indicators of graft
dysfunction and risk for graft failure even when angio-
graphic changes are mild in children after heart
transplantation.
TRANSLATIONAL OUTLOOK: Prospective studies of
speciﬁc surveillance regimens and interventions to pre-
vent the development of CAV should include assessments
of ventricular systolic and diastolic function.
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